1Haag M (2003) Essential fatty acids and the brain. Can J Psychiatry 48, 195–203.
2Ruxton CHS, Calder PC, Reed SC & Simpson MJA (2005) The impact of long chain n-3 polyunsaturated fatty acids on human health. Nutr Res Rev 18, 113–129.
3Ma J, Folsom AR, Eckfeldt JH, Lewis L & Chambless LE; the Atherosclerosis Risk in Communities (ARIC) Study Investigators (1995) Short- and long-term repeatability of fatty acid composition of human plasma phospholipids amd cholestrol esters. Am J Clin Nutr 62, 572–578.
4British Nutrition Foundation (1999) BNF Briefing Paper: n-3 Fatty Acids and Health. London: British Nutrition Foundation.
5James MJ, Gibson RA & Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71, 343S–348S.
6Simopoulos AP (1999) Evolutionary aspects of omega-3 fatty acids in the food supply. Prostaglandins Leukot Essent Fatty Acids 60, 421–429.
7Gregory J, Foster K, Tyler H & Wiseman M (2000) National Diet and Nutritional Survey of British Adults. London: H.M. Stationery Office.
8Bourre JM, Faivre A, Dumont O, Nouvelot A, L'Oudes C, Puymirat J & Tixier-Vidal A (1983) Effect of polyunsaturated fatty acids on fetal mouse brain cells in culture in a chemically defined medium. J Neurochem 41, 1234–1242.
9Bourre JM, Pascal G, Durand G, Masson M, Dumont O & Piciotti M (1984) Alterations in the fatty acid composition of rat brain cells (neurons, astrocytes, and oligodendrites) and of subcellular fractions (myelin and synaptosomes) induced by a diet devoid of n-3 fatty acids. J Neurochem 43, 342–348.
10Ehringer W, Belcher D, Wassall SR & Stillwell W (1990) A comparison of the effects of linolenic acid (18:3Ω3) and docosahexaenoic (22:6Ω3) acids on phospholipid bilayers. Chem Phys Lipids 54, 79–88.
11Tappia PS, Ladha S, Clark DC & Grimble RF (1997) The influence of membrane fluidity, TNF receptor binding, cAMP production and GTPase activity on macrophage cytokine production in rats fed a variety of fat diets. Mol Cell Biochem 166, 135–143.
12Hirashima F, Parow AM, Stoll AL, Demopulos CM, Damico KE, Rohan ML, Eskesen JG, Zuo CS, Cohen BM & Renshaw PF (2004) Omega-3 fatty acid treatment and T2 whole brain relaxation times in bipolar disorder. Am J Psychiatry 161, 1922–1924.
13De la Presa Owens S & Innis SM (1999) Docosahexaenoic and arachidonic acid prevent a decrase in dopaminergic and serotoninergic neurotransmitters in frontal cortex caused by a linoleic and α-linolenic acid deficient diet in formula fed piglets. J Nutr 129, 2088–2093.
14Delion S, Chalon S, Herault J, Guilloteau D, Besnard JC & Durand G (1994) Chronic dietary α-linolenic acid deficiency alters dopaminergic and serotinergic neurotransmission in rats. J Nutr 124, 2466–2476.
15Delion S, Chalon S, Guilloteau D, Besnard JC & Durand G (1996) α-Linolenic acid dietary deficiency alters age related changes in dopaminergic and serotinergic neurotransmission in the rat frontal cortex. J Neurochem 66, 1582–1591.
16McNamara RK, Richtand NM & Levant B (2006) Omega-3 fatty acid deficiency decreases dopamine D2 receptor binding and increases serotonin 5-HT2A receptor binding in the adult rat prefrontal cortex. Biol Psychiatry 59, 146S.
17Takeuchi T, Fukumoto Y & Harada E (2002) Influence of a dietary n-3 fatty acid deficiency on the cerebral catecholamine contents, EEG and learning ability in rat. Behav Brain Res 131, 193–203.
18Zimmer L, Vancassel S, Cantagrel S, Breton P, Delamanche S, Guilloteua D, Durand G & Chalon S (2002) The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am J Clin Nutr 75, 662–667.
19Yao JK, Magan S, Sonel AF, Gurklis JA, Sanders R & Reddy RD (2004) Effects of omega-3 fatty acid on platelet serotonin responsivity in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 71, 171–176.
20Hamazaki K, Itomura M, Huan M, Nishizawa H, Sawazaki S, Tanouchi M, Watanabe S, Hamazaki T, Terasawa K & Yazawa K (2005) Effects of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo controlled, double blind trial. Nutrition 21, 705–710.
21Sawazaki S, Hamazaki T, Yazawa K & Kobayashi M (1999) The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: a double blind placebo controlled study. J Nutr Sci Vitaminology 45, 655–665.
22Calder PC (2003) n-3 Polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38, 342–352.
23Yao JK, Sistilli CG & van Kammen DP (2003) Membrane polyunsaturated fatty acids and CSF cytokines in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 69, 429–436.
24Caughey GE, Mantzioris E, Gibson RA, Cleland LG & James MJ (1996) The effect on human tumor necrosis factor α and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 63, 116–122.
25Rallidis LS, Paschos G, Liakos GK, Velissaridou AH, Anastasiadis G & Zampelas A (2003) Dietary α-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis 167, 237–242.
26Kearns SD & Haag M (1999) The effects of omega-3 fatty acids on Ca-ATPase in rat cerebral cortex. Prostaglandins Leukot Essent Fatty Acids 67, 303–308.
27Bourre JM, Francois M, Youyou A, Dumont O, Piciotti M, Pascal G & Durand G (1989) The effects of dietary α-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats. J Nutr 119, 1880–1892.
28Ahmad A, Moriguchi T & Salem N (2002) Decrease in neuron size in docosahexaenoic acid-deficient brain. Pediatr Neurol 26, 210–218.
29Ikemoto A, Nitta A, Furukawa S, Ohishi M, Nakamura A, Fujii Y & Okuyama H (2000) Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci Lett 285, 99–102.
30Hibbeln JR & Salem N (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 62, 1–9.
31Smith RS (1991) The macrophage theory of depression. Med Hypotheses 35, 298–306.
32Horrobin DF (1998) The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 30, 193–208.
33American Psychiatric Association (1994) Diagnostic and Statistical Manual for Psychiatric Disorders, 4th ed.Washington, DC: American Psychiatric Association.
34Hibbeln JR (1998) Fish consumption and major depression. Lancet 351, 1213.
35Weissman MM, Bland RC, Canino GJ, et al. . (1996) Cross-national epidemiology of major depression and bipolar disorder. JAMA 276, 293–299.
36Hibbeln JR (2002) Seafood consumption, the DHA content of mother's milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Dis 69, 15–29.
37Noaghiul S & Hibbeln JR (2003) Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry 160, 2222–2227.
38World Health Organization (1996) Fish and Fishery Products: World Apparent Consumption Based on Food Balance Sheets (1961–1993). Rome: WHO.
39Peet M (2004) International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. Br J Psychiatry 184, 404–408.
41Tanskanen A, Hibblen JR, Hintikka J, Haatainen K, Honkalampi K & Viinamaki K (2001) Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry 58, 512–513.
42Tanskanen A, Hibbeln JR & Tuomilehto J (2001) Fish consumption and depressive symptoms in the general population in Finland. Psychiatr Serv 52, 529–531.
43Silvers KM & Scott KM (2002) Fish consumption and self-reported physical and mental health status. Public Health Nutr 5, 427–431.
44Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D & Lonnqvist J (2004) Is dietary intake of omega-3 fatty acids associated with depression? Am J Psychiatry 161, 567–569.
45Jacka FN, Pasco JA, Henry MJ, Kotowicz MA, Nicholson GC & Berk M (2004) Dietary omega-3 fatty acids and depression in a community sample. Nutr Neurosci 7, 101–106.
46Suzuki S, Akechi T, Kobayashi M, Taniguchi K, Goto K, Sasaki S, Tsugane S, Nishiwaki Y, Miyaoka H & Uchitomi Y (2004) Daily omega-3 fatty acid intake and depression in Japanese patients with newly diagnosed lung cancer. Br J Cancer 90, 787–793.
47Timonen M, Horrobin DF, Jokelainen J, Laitinen J, Herva A & Rasanen P (2004) Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord 82, 447–452.
48Barberger-Gateau P, Jutand MA, Letenneur L, Larrieu S, Tavernier B & Berr C for the 3C Study Group (2005) Correlates of regular fish consumption in French elderly community dwellers: data from the Three-City study. Eur J Clin Nutr 59, 817–825.
49Miyake Y, Sasaki A, Yokoyama T, et al. . (2006) Risk of postpartum depression in relation to dietary fish and fat intake in Japan: the Osaka Maternal and Child Health Study. Psychol Med 36, 1727–1737.
50Appleton KM, Peters TJ, Hayward RC, Heatherley SV, McNaughton SA, Rogers PJ, Gunnell D, Ness AR & Kessler D (2007) Depressed mood and n-3 polyunsaturated fatty acid intake from fish: non-linear or confounded association? Soc Psychiatry Psychiatr Epidemiol 42, 100–104.
51Appleton KM, Woodside JV, Yarnell JWG, et al. . (2007) Depressed mood and dietary fish intake: direct relationship or indirect relationship as a result of diet and lifestyle? J Affect Disord 104, 217–223.
52Rodda BE, Miller MC & Bruhn JG (1971) Prediction of anxiety and depression patterns among coronary patients using a Markov Process Analysis. Comp Behav Sci 16, 482–489.
53Beck AT & Steer RA (1987) Beck Depression Inventory Manual. San Antonio, TX: Psychological Corporation.
54Ware JE & Sherbourne CD (1992) The MOS36-item short form health survey (SF-36). Conceptual framework and item selection. Med Care 30, 473–483.
55Zigmond AS & Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67, 361–370.
56Winokur A, Winokur DF, Rickels K & Cox DS (1984) Symptoms of emotional distress in a family planning service: stability over a four-week period. Br J Psychiatry 144, 395–399.
57Radloff LS (1977) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measures 1, 385–401.
58Cox JL, Holden JM & Sagovsky R (1987) Detection of postnatal depression development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 150, 782–786.
59Lovibond SH & Lovibond PF (1995) Manual for the Depression, Anxiety and Stress Scales. Sydney: Psychology Foundation of Australia Inc.
60Ellis FA & Sanders TAB (1977) Long chain polyunsaturated fatty acids in endogenous depression. J Neurol Neurosurg Psychiatry 40, 168–169.
61Fehily AMA, Bowey OAM, Ellis FR & Meade BW (1981) Plasma and erythrocyte membrane long chain polyunsaturated fatty acids in endogenous depression. Neurochem Int 3, 37–42.
62Maes M, Smith R, Christophe A, Cosyns P, Desnyder R & Meltzer H (1996) Fatty acid composition in major depression: decreased ω3 fractions in cholesterol esters and increased C20:4ω6/C20:5ω3 ratio in cholesterol esters and phospholipids. J Affect Disord 38, 35–46.
63Peet M, Murphy B, Shay J & Horrobin D (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 43, 315–319.
64Edwards R, Peet M, Shay J & Horrobin D (1998) Depletion of docosahexaenoic acid in red blood cell membranes of depressive patients. Biochem Soc Trans 26, S142.
65Maes M, Christophe A, Delanghe J, Altamura C, Neels H & Meltzer HY (1999) Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 85, 275–291.
66Tiemeier H, van Tuijl HR, Hofman A, Kiliaan AJ & Breteler MMB (2003) Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam Study. Am J Clin Nutr 78, 40–46.
67Parker GB, Heruc GA, Hilton TM, Olley A, Brotchie H, Hadzi-Pavlovic D, Friend C, Walsh WF & Stocker R (2006) Low levels of docosahexaenoic acid identified in acute coronary syndrome patients with depression. Psychiatry Res 141, 279–286.
68Frasure-Smith N, Lesperance F & Julien P (2004) Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol Psychiatry 55, 891–896.
69Schins A, Crijns HJ, Brummer RJ, Wichers M, Lousberg R, Celis S & Honig A (2007) Altered omega-3 polyunsaturated fatty acid status in depressed post-myocardial infarction patients. Acta Psychiatr Scand 115, 35–40.
70De Vriese SR, Christophe AB & Maes M (2003) Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci 73, 3181–3187.
71Assies J, Lok A, Bockting CL, Weverling GJ, Lieverse R, Visser I, Abeling NGGM, Duran M & Schene AH (2004) Fatty acids and homocysteine levels in patients with recurrent depression: an explorative study. Prostaglandins Leukot Essent Fatty Acids 70, 349–356.
72McNamara RK, Hahn CG, Jandacek R, Rider T, Tso P, Stanford KE & Richtand NM (2007) Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry 62, 17–24.
73Mamalakis G, Tornaritis M & Kafatos A (2002) Depression and adipose essential polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 67, 311–318.
74Mamalakis G, Kiriakakis M, Tsibinos G & Kafatos A (2004) Depression and adipose polyunsaturated fatty acids in an adolescent group. Prostaglandins Leukot Essent Fatty Acids 71, 289–294.
75Kobayakawa M, Yamawaki S, Hamazaki K, Akechi T, Inagaki M & Uchitomi Y (2005) Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer. Br J Cancer 93, 1329–1333.
76Mamalakis G, Jansen E, Cremers H, Kiriakakis M, Tsibinos G & Kafatos A (2006) Depression and adipose and serum cholesteryl ester polyunsaturated fatty acids in the survivors of the seven countries study population of Crete. Eur J Clin Nutr 60, 1016–1023.
77Otto SJ, de Groot RHM & Hornstra G (2003) Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status. Prostaglandins Leukot Essent Fatty Acids 69, 237–243.
78Browne JC, Scott KM & Silvers KM (2006) Fish consumption in pregnancy and omega-3 status after birth are not associated with postnatal depression. J Affect Disord 90, 131–139.
79Huan M, Hamazaki K, Sun Y, Itomura M, Liu H, Kang W, Watanabe S, Terasawa K & Hamazaki T (2004) Suicide attemtpt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol Psychiatry 56, 490–496.
80Chiu CC, Huang SY, Su KP, Lu ML, Huang MC, Chen CC & Shen WW (2003) Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol 13, 99–103.
81Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB & Mahadik SP (2003) Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121, 109–122.
82Garland MR, Hallahan B, McNamara M, Carney PA, Grimes H, Hibbeln JR, Harkin A & Conroy RM (2007) Lipids and essential fatty acids in patients presenting with self-harm. Br J Psychiatry 190, 112–117.
83Kaiya H, Horrobin DF, Manku MS & Morse-Fisher N (1991) Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol Psychiatry 30, 357–362.
84Biggs JT, Wylie LT & Ziegler VE (1978) Validity of the Zung self-rating depression scale. Br J Psychiatry 132, 381–385.
85Sheikh JL & Yesavage JA (1986) Geriatric depression scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 5, 165–173.
86Adams PB, Lawson S, Sanigorski A & Sinclair AJ (1996) Arachidonic to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids 31, S167–S176.
87Mamalakis G, Kiriakakis M, Tsibinos G, Hatzis C, Flouri S, Mantzoros C & Kafatos A (2006) Depression and serum adiponectin and adipose omega-3 and omega-6 fatty acids in adolescents. Pharmacol Biochem Behav 85, 474–479.
88Mamalakis G, Kalogeropoulos N, Andikopoulos N, Hatzis C, Kromhout D, Moschandrea J & Kafatos A (2006) Depression and long chain n-3 fatty acids in adipose tissue in adults from Crete. Eur J Clin Nutr 60, 882–888.
89Llorente AM, Jensen CL, Voigt RG, Fraley JK, Berretta MC & Heird WC (2003) Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol 188, 1348–1353.
90Kilkens TOC, Honig A, Maes M, Lousberg R & Brummer R-JM (2004) Fatty acid profile and affective dysregulation in irritable bowel syndrome. Lipids 39, 425–431.
91Assies J, Lieverse R, Vreken P, Wanders RJA, Dingemans PMJA & Linszen DH (2001) Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 49, 510–522.
92Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA & Mann JJ (2006) Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry 163, 1100–1102.
93Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23, 56–62.
94Parker G, Hilton T, Bains J & Hadzi-Pavlovic D (2002) Cognitive-based measures screening for depression in the medically ill: the DMI-10 and the DMI-18. Acta Psychiatr Scand 105, 419–426.
95Arrindell WA & Ettema JHM (1986) SCL-90. Een Mulitdimensionale Psychopathologie Indicator (SCL-90. A Mulitdimensional Psychopathology Indicator). Lisse, The Netherlands: Swets and Zeitling Ltd.
96Montgomery SA & Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134, 382–389.
97Beck AT, Schuyler D & Herman I (1974) . In The Prediction of Suicide, pp. 45–56 [Beck AT, Resnick H and Lettieri D, editors]. Bowie, MD: Charles Press.
98Freeman MP, Hibbeln JR, Wisner KL, Watchman M & Gelenberg AJ (2006) An open trial of omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatr 18, 21–24.
99Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M & Gelenberg AJ (2006) Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 113, 31–35.
100Osher Y, Bersudsky Y & Belmaker RH (2005) Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 66, 726–729.
101Wozniak J, Biederman J, Mick E, Waxmonsky J, Hantsoo L, Best C, Cluette-Brown JE & Laposata M (2007) Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 17, 440–447.
102Sagduyu K, Dokucu ME, Eddy BA, Craigen G, Baldassano CF & Yildiz A (2005) Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J 4, 6.
103Chiu CC, Huang SY, Shen WW & Su KP (2003) Omega-3 fatty acids for depression in pregnancy. Arch Gen Psychiatry 60, 385.
104Puri BK, Richardson AJ & Horrobin DF (2002) Eicosapentaenoic acid in treatment-resistant depression. Arch Gen Psychiatry 59, 91–92.
105Marangell LB, Martinez JM, Zboyan HA, Chong H & Puryear LJ (2004) Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary open-label pilot study. Depress Anx 19, 20–23.
106Kaplan Z, Matar M, Kamin R & Cohen H (2005) Possible deleterious effects of adjunctive omega-3 fatty acids in post-traumatic stress disorder. Neuropsychiatr Dis Treat 1, 187–190.
107Nemets B, Stahl Z & Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 159, 477–479.
108Peet MB & Horrobin DF (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 59, 913–919.
109Marangell LB, Martinez JM, Zboyan HA, Kertz B, Seung Kim HF & Puryear LJ (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 160, 996–998.
110Su K-P, Huang S-Y, Chiu C-C & Shen WW (2003) Omega-3 fatty acids in major depressive disorder – a preliminary double-blind placebo-controlled trial. Eur Neuropsychopharmacol 13, 267–271.
111Silvers KM, Woolley CC, Hamilton FC, Watts PM & Watson RA (2005) Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 72, 211–218.
112Nemets H, Nemets B, Apter A, Bracha Z & Belmaker RH (2006) Omega-3 treatment of children's depression: a controlled, double-blind pilot study. Am J Psychiatry 163, 1098–1100.
113Grenyer BFS, Crowe T, Meyer B, Owen AJ, Grigonis EM, Caputi P & Howe PRC (2007) Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 31, 1393–1396.
114Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK & Marangell LB (1999) Omega-3 fatty acids in bipolar disorder – a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56, 407–412.
115Frangou S, Lewis M & McCrone P (2006) Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 188, 46–50.
116Keck PE Jr, Mintz J, McElroy SL, et al. . (2006) Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60, 1020–1022.
117Ness AR, Gallacher JEJ, Bennett PD, Gunnell DJ, Rogers PJ, Kessler D & Burr ML (2003) Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutr Neurosci 6, 63–65.
118Fontani G, Corradeschi F, Felici A, Alfatti F, Bugarini R, Fiaschi AI, Cerretani D, Montorfani G, Rizzo AM & Berra B (2005) Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with omega-3 polyunsaturated fatty acids. Eur J Clin Invest 35, 499–507.
119Rogers PJ, Appleton KM, Kessler D, Peters TJ, Gunnell D, Hayward RC, Heatherley SV, Christian LM, McNaughton SA & Ness AR (2008) No effect of n-3 long chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomized controlled trial. Br J Nutr 99, 421–431.
120Behan PO, Behan WMH & Horrobin D (1990) Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 82, 209–216.
121Warren G, McKendrick M & Peet M (1999) The role of essential fatty acids in chronic fatigue syndrome. Acta Neurol Scand 99, 112–116.
122Fenton WS, Dickerson F, Boronow J, Hibbeln JR & Knable M (2001) A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 158, 2071–2074.
123Peet M & Horrobin DFin association with the E-E Multicentre Study Group (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatric Res 36, 7–18.
124Zanarini MC & Frankenburg MD (2003) Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 160, 167–169.
125Fux M, Benjamin J & Nemets B (2004) A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psych Res 38, 323–325.
126Hallahan B, Hibbeln JR, Davis JM & Garland MR (2007) Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry 190, 118–122.
127Reynolds W & Kobak K (1995) Hamilton Depression Inventory: A Self-Report Version of the Hamilton Depression Rating Scale, Professional Manual. Odessa, FL: Psychological Assessment Resources.
128Poznanski EO, Cook SC & Carroll BJ (1979) A depression rating scale for children. Pediatrics 64, 442–450.
129Kovacs M & Beck AT (1977) . In Depression in Childhood [Schulterbrandt JG and Raskin A, editors]. New York, NY: Raven.
130Guy W (1976) ECDEU Assessment Manual for Psychopharmacology: Publication ADM 70–338, pp. 218–222. Washington, DC: US Department of Health, Education and Welfare.
131Young RC, Biggs JT, Ziegler VE & Meyer DA (1978) A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 133, 429–435.
132Rush AJ, Gullion CM, Basco MR, Jarrett RB & Trivedi MH (1996) The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 26, 477–486.
133Spearing MK, Post RM, Leverich GS, Brandt D & Nolen W (1997) Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 73, 159–171.
134First MB, Spitzer RL, Gibbon M & Williams JBW (1997) Structured Clinical Interview for DSM IV Axis I Disorders – Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press.
135Derogatis LR (1987) ‘The Derogatis Stress Profile (DSP)’: quantifications of psychological stress. Adv Psychosom Med 14, 30–54.
136McNair DM, Lorr M & Droppleman LF (1981) Manual of the Profile of the Mood States. San Diego, CA: Educational and Industrial Testing Service.
137Coccaro EF, Harvey PD, Kupsaw-Lawrence E, Herbert JL & Bernstein DP (1991) Development of neuropharmacologically based behavioural assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 3, S44–S51.
138Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D & Ness AR (2006) Effects of n-3 long chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 84, 1308–1316.
139Freeman MP, Hibblen JR, Wisner KL, et al. . (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67, 1954–1967.
140Lin P-Y & Su K-P (2007) A meta-analytic review of double-blind, placebo-controlled trials of anti-depressant efficacy of omega-3 fatty acids. J Clin Psychiatry 68, 1056–1061.
141Appleton KM, Rogers PJ & Ness AR (2008) . In Fish Oils and Health [Heikkinen E. P., editor]. New York: Nova Science Publishers, Inc. (In the Press).
142Anonymous (1998) Collins English Dictionary. Glasgow: HarperCollins Publishers.
143Green P, Hermesh H, Monselise A, Marom S, Presburger G & Weizman A (2006) Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder. Eur Neuropsychopharmacol 16, 107–113.
144Yehuda S, Rabinovitz S & Mostofsky DI (2005) Mixture of essential fatty acids lowers test anxiety. Nutr Neurosci 8, 265–267.
145Holmes GP, Kaplan JE, Gantz NM, et al. . (1988) Chronic fatigue syndrome: a working definition. Ann Int Med 108, 387–389.
146Maes M, Mihaylova I & Leunis JC (2005) In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. Neuro Endocrinol Lett 26, 745–751.
147Puri BK (2004) The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome. Prostaglandins Leukot Essent Fatty Acids 70, 399–401.
148Cook WW & Medley DM (1954) Proposed hostility and pharisaic-vitrue scales for the MMPI. J Appl Psychol 38, 414–418.
149Iribarren C, Markovitz JH, Jacobs DR Jr, Schreiner PJ, Daviglus M & Hibbeln JR (2004) Dietary intake of n-3, n-6 fatty acids and fish: relationship with hostility in young adults – the CARDIA study. Eur J Clin Nutr 58, 24–31.
150Buydens-Branchey L, Branchey M, McMakin DL & Hibbeln JR (2003) Polyunsaturated fatty acid status and aggression in cocaine addicts. Drug Alcohol Depend 71, 319–323.
151Umhau JC, Dauphinais KM, Patel SH, Nahrwold DA, Hibbeln JR & Rawlings RR (2006) The relationship between folate and docosahexaenoic acid in men. Eur J Clin Nutr 60, 352–357.
152Virkkunen ME, Horrobin DF, Jenkins DK & Manku MS (1987) Plasma phospholipid essential fatty acids and prostaglandins in alcoholic, habitually violent and impulsive offenders. Biol Psychiatry 22, 1087–1096.
153Hamazaki T, Sawazaki S, Itomura M, Asaoka E, Nagao Y, Nishimura N, Yazawa K, Kuwamori T & Kobayashi M (1996) The effect of docosahexaenoic acid on aggression in young adults: a placebo-controlled double-blind study. J Clin Invest 97, 1129–1133.
154Hamazaki T, Sawazaki S, Nagao Y, Kuwamori T, Yazawa K, Mizushima Y & Kobayashi M (1998) Docosahexaenoic acid does not affect aggression of normal volunteers under non-stressful conditions: a randomized, placebo-controlled, double-blind study. Lipids 33, 663–667.
155Hamazaki T, Thienprasert A, Kheovichai K, Samuhaseneetoo S, Nagasawa T & Watanabe S (2002) The effect of docosahexaenoic acid on aggression in elderly Thai subjects – a placebo-controlled double-blind study. Nutr Neurosci 5, 37–41.
156Itomura M, Hamazaki K, Sawazaki S, Kobayashi M, Terasawa K, Watanabe S & Hamazaki T (2005) The effect of fish oil on physical aggression in schoolchildren – a randomized, double-blind, placebo-controlled trial. J Nutr Biochem 16, 163–171.
157Hirayama S, Hamazaki T & Terasawa K (2004) Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder – a placebo-controlled double-blind study. Eur J Clin Nutr 58, 467–473.
158Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH & Feucht M (2007) Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 61, 551–553.
159Buydens-Branchey L & Branchey M (2006) n-3 Polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 26, 661–665.
160Gesch CB, Hammond SM, Hampson SE, Eves A & Crowder MJ (2002) Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners: randomised placebo-controlled trial. Br J Psychiatry 181, 22–28.
161Rosenzweig S (1978) Rosenzweig Picture-Frustration Study: Basic Manual. St Louis, MO: Rana House.
162Hayashi K, Sumita K, Ichitani T, Nakata Y, Hata K, Tsuda K, Nishio H & Nishikawa M (1987) PF Study. Kaisetsu (in Japanese). Kyoto, Japan: Sankyobo.
163Yamasaki K, Sakai A, Soga S, Ohdo O, Shimai T & Ohkate K (2001) Reconstruction of subscales in the Hostility-Aggression Questionnaire for Children (HAQ-C) and considerations of aggresiveness construct (article in Japanese). Naruto Kyouikudaigaku Kenkyukiyou 16, 1–10.
164Buss AH & Perry M (1992) The aggression questionnaire. J Pers Soc Psychol 63, 452–459.
165Spielberger CD (1991) State-Trait Anger Expression Inventory: Professional Manual. Odessa, FL: Psychological Assessment Resources Inc.
166Aman MG, Singh NN, Stewart AW & Field CJ (1985) The aberrant behaviour checklist: a behaviour rating scale for the assessment of treatment effects. Am J Mental Defic 89, 485–491.
167Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C & Golding J (2007) Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort. Lancet 369, 578–585.
168Mitchell EA, Aman MG, Turbott SH & Manku M (1987) Clinical characteristics and serum essential fatty acids levels in hyperactive children. Clin Pediatrics 26, 406–411.
169Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, Lipp SR & Burgess JR (1995) Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 62, 761–768.
170Stevens L, Zhang W, Peck L, Kuczek T, Grevstad N, Mahon A, Zentall SS, Arnold LE & Burgess JR (2003) EFA supplementation in children with inattention, hyperactivity and other disruptive behaviours. Lipids 38, 1007–1021.
171Young GS, Maharaj NJ & Conquer JA (2004) Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids 39, 117–123.
172Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K & Burgess JR (2006) Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 75, 299–308.
173Stevens LJ, Zentall SS, Abate ML, Kuczek T & Burgess JR (1996) Omega-3 fatty acids in boys with behavior, learning and health problems. Physiol Behav 59, 915–920.
174Joshi K, Lad S, Kale M, Patwardhan B, Mahadik SP, Patni B, Chaudhary A, Bhave S & Pandit A (2006) Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids 74, 17–21.
175Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC & Heird WC (2001) A randomized double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatrics 139, 189–196.
176Harding KL, Judah RD & Gant CE (2003) Outcome-based comparison of Ritalin versus food-supplement treated children with AD/HD. Alt Med Rev 8, 319–330.
177Richardson AJ & Puri BK (2002) A randomized double-blind, placebo controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychopharmacol Biol Psychiatry 26, 233–239.
178Richardson AJ & Montgomery P (2005) The Oxford-Durham Study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 115, 1360–1366.
179Greenberg LM & Kindschi CL (1996) TOVA Test of Variables of Attention: Clinical Guide. Odessa, FL: Psychological Assessment Resources.
180D'Elia LF, Satz P, Uchiyama CL & White T (1995) Color Trails Test 1 and 2. Odessa, FL: Psychological Assessment Resources.
181Achenbach TM & Edenbrock KC (1983) Manual for the Child Behavior Checklist and Revised Child Behavior Profile. Burlington, VT: University of Vermont Department of Psychiatry.
182Conners CK (1997) Conners' Parent Rating Scales – Revised. North Tonawanda, New York: Multi-Health Systems.
183Seckler P, Burns W, Montgomery D & Sandford JA (1995) A Reliability Study of IVA: Intermediate Visual and Auditory Continuous Performance Test, , Washington, DC.
184Conners C (1990) Conners' Abbreviated Symptom Questionnaire. North Tonawanda, NY: Multi-Health Systems.
185Pelham WE, Gnagy EM, Greenslade KE & Milich R (1992) Teacher ratings of DSM IIIR symptoms for the disruptive behaviour disorders. J Am Acad Child Psychiatry 24, 756–764.
186Dougherty DM, Marsh DM & Mathias CW (2002) Immediate and delayed memory tasks: a computerized behavioral measure of memory, attention and impulsivity. Behav Res Methods, Insturm Comput 34, 391–398.
187Christensen O & Christensen E (1988) Fat consumption and schizophenia. Acta Psychiatr Scand 78, 587–591.
188Strassnig M, Singh Brar J & Ganguli R (2005) Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. Schizophr Res 76, 343–351.
189Obi FO & Nwanze EAC (1979) Fatty acid profiles in mental disease: lineolate variations in schizophrenia. J Neurobiol Sci 43, 447–454.
190Horrobin DF, Manku MS, Morse-Fisher N, Vaddadi KS, Courtney P, Glen IM, Glen E, Spellman M & Bates C (1989) Essential fatty acids in plasma phospholipids in schizophrenics. Biol Psychiatry 25, 562–568.
191Yao JK, van Kammen DP & Welker JA (1994) Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 13, 217–226.
192Peet M, Laugharne J, Rangarajan N, Horrobin D & Reynolds G (1995) Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr Res 29, 227–232.
193Yao JK, Leonard S & Reddy RD (2000) Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42, 7–17.
194Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV & Mahadik SP (2002) Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with anti-psychotics. Schizophr Res 58, 1–10.
195Landen M, Davidsson P, Gottfries CG, Mansson JE & Blennow K (2002) Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophr Res 55, 83–88.
196Arvindakshan M, Ghate M, Ranjekar PK, Evans DR & Mahadik SP (2003) Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 62, 195–204.
197Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF & Mahadik SP (2003) Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 69, 393–399.
198Peet M, Shah S, Selvam K & Ramchand CN (2004) Polyunsaturated fatty acid levels in red cell membranes of unmedicated schizophrenic patients. World J Biol Psychiatry 5, 92–99.
199Reddy RD, Keshavan MS & Yao JK (2004) Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 30, 901–911.
200Kemperman RFJ, Veurink M, van der Wal T, Knegtering H, Bruggeman R, Fokkema MR, Kema IP, Korf J & Muskiet FAJ (2006) Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation. Prostaglandins Leukot Essent Fatty Acids 74, 75–85.
201McNamara RK, Jandacek R, Rider T, Tso P, Hahn CG, Richtand NM & Stanford KE (2007) Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. Schizophr Res 91, 37–50.
202Mellor JE, Laugharne JDE & Peet M (1996) Omega-3 fatty acid supplementation in schizophrenic patients. Hum Psychopharmacol 11, 39–46.
203Richardson AJ, Cyhlarova E & Ross MA (2003) Omega-3 and omega-6 fatty acid concentrations in red blood cell membranes relate to schizotypal traits in healthy adults. Prostaglandins Leukot Essent Fatty Acids 69, 461–466.
204Shah S, Vankar GK, Telang SD, Ramchand CN & Peet M (1998) Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia. Schizophr Res 29, 158.
205Rudin DO (1981) The major psychoses and neuroses as omega-3 essential fatty aid deficiency syndrome: substrate pellagra. Biol Psychiatry 16, 837–850.
206Puri BK & Richardson AJ (1998) Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Arch Gen Psychiatry 55, 188–189.
207Peet M, Brind J, Ramchand CN, Shah S & Vankar GK (2001) Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 49, 243–251.
208Emsley R, Myburgh C, Oosthuizen P & van Rensburg SJ (2002) Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 159, 1596–1598.
209Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, Andres C & Chalon S (2001) Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 65, 1–7.
210Bell JG, MacKinley EE, Dick JR, MacDonald DJ, Boyle RM & Glen ACA (2004) Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids 71, 201–204.
211Johnson SM & Hollander E (2003) Evidence that eicosapentanoic acid is effective in treating autism. J Clin Psychiatry 64, 848–849.
212DiMatteo MR, Lepper HS & Croghan TW (2000) Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160, 2101–2107.
213Burdge GC, Finnegan YE, Minihane AM, Williams CM & Wootton SA (2003) Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of 13C α-linolenic acid to longer-chain fatty acids and partitioning towards β-oxidation in older men. Br J Nutr 90, 311–321.
214Gulyaeva NV, Levishina IP & Obidin AB (1989) Indicies of free-radical oxidation of lipids and antiradical protection of the brain: neurochemical correlates of the development of the general adaptation syndrome. Neurosci Behav Physiol 19, 367–382.
215Mills DE, Huang YS, Nane M & Poisson JP (1994) Psychosocial stress, catecholamines, and essential fatty acid metabolism in rats. Soc Exp Biol Med 205, 56–61.
216Brenner RR (2003) Hormonal modulation of Δ6 and Δ5 desaturases: case of diabetes. Prostaglandins Leukot Essent Fatty Acids 68, 151–162.
217Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J & Fenton WS (2003) Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol Psychiatry 53, 431–441.
218Reddy RD & Yao JK (2003) Environmental factors and membrane polyunsaturated fatty acids in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 69, 385–391.
219Hasanah CI, Khan UA, Musalmah M & Razali SM (1997) Reduced red-cell folate in mania. J Affect Disord 46, 95–99.
220Stoney CM & Engebretson TO (2000) Plasma homocysteine concentrations are positively associated with hostility and anger. Life Sci 66, 2267–2275.
221Durand P, Prost M & Blache D (1996) Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 121, 231–243.
222Hirono H & Wada Y (1978) Effects of dietary folate deficiency on developmental increase of myelin lipids in rat brain. J Nutr 108, 766–772.
223Bekaroglu M, Aslan Y, Gedik Y, Deger O, Mocan H, Erduran E & Karahan C (1996) Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry 37, 225–227.
224Starobrat-Hermelin B & Kozielec T (1997) The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD). Positive response to magnesium oral loading test. Magnes Res 10, 149–156.
225Arnold LE, Bozzolo H, Hollway J, Cook A, DiSilvestro RA, Bozzolo DR, Crowl L, Ramadan Y & Williams C (2005) Serum zinc correlates with parent- and teacher-rated inattention in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15, 628–636.
226Akhondzadeh S, Mohammadi M-R & Khademi M (2004) Zinc sulphate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial (ISRCTN64132371). BMC Psychiatry 4, 9.
227Galland L (1985) Impaired fatty acid metabolism in latent tetany. Magnesium 4, 333–338.
228Arnold LE & DiSilvestro RA (2005) Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15, 619–627.
229Bolton-Smith C, Woodward M & Tavendale R (1997) Evidence for age related differences in the fatty acid composition of human adipose tissue, independent of diet. Eur J Clin Nutr 51, 619–624.
230Burdge GC & Calder PC (2006) Dietary α-linolenic acid and health-related outcomes: a metabolic perspective. Nutr Res Rev 19, 26–52.
231Sontrop J & Campbell MK (2005) ω-3 Polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev Med 42, 4–13.
232Visioli F, Rise P, Barassi MC, Marangoni F & Galli C (2003) Dietary intake of fish vs. formulations leads to higher plasma concentrations of n-3 fatty acids. Lipids 38, 415–418.
233Brookes KJ, Chen W, Xu X, Taylor E & Asherson P (2006) Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. Biol Psychiatry 60, 1053–1061.
234Horrobin DF, Jenkins K, Bennett CN & Christie WW (2002) Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids 66, 83–90.
235Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ & Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5, 260–267.
236Stoll AL, Damico KE, Daly BP, Severus WE & Marangell LB (2001) Methodological considerations in clinical studies of omega 3 fatty acids in major depression and bipolar disorder. World Rev Nutr Diet 88, 58–67.
237Puri BK & Richardson AK (2000) The effects of olive oil on ω3 fatty acids and mood disorders. Arch Gen Psychiatry 57, 715.
238Covault J, Pettinati H, Moak D, Mueller T & Kranzler HR (2004) Association of a long-chain fatty acid-CoA ligase 4 gene polymorphism with depression and with enhanced niacin-induced dermal erythema. Am J Med Genetics 127, 42–47.
239Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Jun TY, Lee C & Paik IH (2004) Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmcol 7, 495–500.
240Ross BM (2007) Omega-3 fatty acid deficiency in major depressive disorder is caused by the interaction between diet and a genetically determined abnormality in phospholipid metabolism. Med Hypotheses 68, 515–524.
241Hibbeln JR & Salem N (2001) . In Vitamin D: Molecular Biology, Physiology and Clinical Applications [Holick MF, editor]. Totawa, NJ: Humana Press Inc.
242Peet M (2003) Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. Prostaglandins Leukot Essent Fatty Acids 69, 477–485.
243Ruxton CHS, Reed SC, Simpson MJA & Millington KJ (2007) The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 20, 275–285.
244Shi HJ, Nakamura K, Shimbo M & Takano T (2005) Dietary supplement consumption among urban adults influenced by psychosocial stress: its pronounced influence upon persons with a less healthy lifestyle. Br J Nutr 94, 407–414.
245Van Strater ACP & Bouly PF (2006) Omega-3 fatty acids and mood disorders. Am J Psychiatry 163, 2018.
246Kinrys G (2000) Hypomania associated with ω3 fatty acids. Arch Gen Psychiatry 57, 715–716.
247Marangell LB, Suppes T, Ketter TA, Dennehy EB, Zboyan H, Kertz B, Nierenberg A, Calabrese J, Wisniewski SR & Sachs G (2006) Omega-3 fatty acids in bipolar disorder: clinical and research considerations. Prostaglandins Leukot Essent Fatty Acids 75, 315–321.
248Skosnik PD & Yao JK (2003) From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids 69, 367–384.